USA

Under the agreement, the companies will identify and implement targeted applications of agentic AI, an AI systems designed to perform tasks and execute workflows with varying degrees of autonomy.

Located in Kendall Square, a major biotechnology and life sciences hub, the new centre will operate alongside AstraZeneca’s genomic medicine facility at 100 Binney Street.

IntraBio will become a wholly owned subsidiary of Shionogi Inc., the Japanese group’s US-based subsidiary in New Jersey.

The planned campus at the New Albany International Business Park will use a flexible, modular design combining drug substance and drug product manufacturing with digital and automation technologies.

The financing comes as NorthStar expands its role in the radiopharmaceutical supply chain, particularly for actinium 225 (Ac 225), an alpha-emitting radioisotope used to develop targeted cancer therapies.

Profluent will conduct the computational design work using its Profluent Protein Atlas, a dataset containing more than 115 billion unique protein sequences.

TLB 33 is a human immunoglobulin G1 monoclonal antibody designed to bind to and neutralise interleukin 33, an immune signalling protein.

The companies have also signed a non-binding MoU covering a broader global programme to evaluate ivonescimab in combination with additional AstraZeneca oncology therapies.

The approval gives AbbVie another Parkinson’s product following its acquisition of Cerevel Therapeutics.

The withdrawal changes the immediate US regulatory path for the ES-SCLC indication, but the ongoing Phase III programme provides the companies with another source of clinical data.